hb002.1m
Recombinant proteinexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 8, 2018 (NCT03387566)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
FLT1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04802980 | Phase 1 | Apr 28, 2020 | Huabo Biopharm Co., Ltd., Huazhong University of Science and Technology |
| NCT03636750 | Phase 1 | Jun 28, 2018 | Huabo Biopharm Co., Ltd. |
| NCT03387566 | Phase 1 | Feb 8, 2018 | Huabo Biopharm Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Huabo Biopharm Co., Ltd. | For profit | 3 | 3 | 1 | 2018 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1